BIO-TECHNE Corp. 10-Q Summary: Quarter Ended March 31, 2025
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2025 (Fiscal Q3 2025) and the nine months ended March 31, 2025. BIO-TECHNE Corp. operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. The company develops and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Net Sales | $316.2 million | $303.4 million | $902.7 million | $853.0 million |
| Gross Margin | $214.6 million (67.9%) | $204.6 million (67.4%) | $591.5 million (65.5%) | $566.4 million (66.4%) |
| Operating Income | $38.7 million | $67.0 million | $126.1 million | $160.9 million |
| Net Earnings | $22.6 million | $49.1 million | $91.1 million | $127.5 million |
| Diluted EPS | $0.14 | $0.31 | $0.57 | $0.79 |
| Cash & Equivalents | $140.7 million | Balance Sheet Data | ||
| Long-Term Debt | $330.0 million | Balance Sheet Data | ||
| Operating Cash Flow (9mo) | $189.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 4% in Q3 and 6% for the nine-month period. Organic revenue grew 6% in both periods, driven by improving pharma end markets and broad-based performance in Diagnostics and Spatial Biology.
- Profitability Decline: Net earnings decreased significantly (54% in Q3, 29% for nine months) primarily due to a non-recurring $38.9 million litigation charge related to a binding arbitration award with a former CEO.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 35% in Q3 and 18% for the nine months, driven by the litigation charge, restructuring costs, and reinstatement of incentive compensation accruals.
- Restructuring: The company incurred $13.7 million in restructuring and restructuring-related costs for the nine months ended March 31, 2025, focused on optimizing the manufacturing footprint and recovering operating margins.
Guidance, Outlook, and Risks
- Capital Allocation: The Board approved a new $500 million share repurchase plan on April 30, 2025. The company also declared a quarterly dividend of $0.08 per share.
- Tax Outlook: The effective tax rate for the quarter was 41.0% due to discrete items. Excluding discrete items, the forecasted tax rate for the remainder of fiscal 2025 is expected to range from 23% to 27%.
- Investments: The company invested $15.0 million in Spear Bio. It holds a forward contract to acquire the remaining 80.1% of Wilson Wolf Corporation, potentially requiring up to $1 billion in payment if milestones are met by 2027.
- Risks: Management highlighted risks related to global trade conditions, including tariffs and import restrictions, which may increase costs and disrupt supply chains. There are no material changes to other risk factors from the previous 10-K.
Investor Verification Checklist
- Arbitration Impact: Verify the finality of the $37.2 million arbitration payment and confirm no further legal exposure remains regarding the former CEO dispute.
- Restructuring Execution: Monitor the timeline and cost realization of the enterprise-wide restructuring aimed at optimizing the manufacturing footprint.
- Wilson Wolf Milestones: Track Wilson Wolf's revenue and EBITDA performance to assess the likelihood of triggering the mandatory $1 billion acquisition payment.
- Organic Growth Sustainability: Assess whether the 6% organic revenue growth is sustainable given the noted headwinds from foreign currency and held-for-sale business exclusions.
- Share Repurchase Pace: Evaluate the execution of the new $500 million buyback program against the remaining authorization from the prior plan.